# Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

> **NCT07157514** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Actinium Pharmaceuticals** · enrollment: 306 (estimated)

## Conditions studied

- Acute Leukemia
- Myeloid Leukemia
- Acute Myelogenous Leukemia
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia, in Relapse
- Myelogenous Leukemia
- Myelogenous Leukemia, Acute
- Myelogenous Leukemia in Relapse
- Transplant-Related Disorder
- Allogeneic Disease
- Refractory AML

## Interventions

- **DRUG:** 131I-apamistamab
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **RADIATION:** Total Body Irradiation (TBI)
- **BIOLOGICAL:** Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

## Key facts

- **NCT ID:** NCT07157514
- **Lead sponsor:** Actinium Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2029-02
- **Final completion:** 2034-02
- **Target enrollment:** 306 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07157514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07157514, "Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT07157514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*